We propose to include damaging CYP51A1 variants in genetic testing to increase the discovery of underlying causes for diseases such as pediatric cataract neonatal hepatic failure, global developmental delay, azole susceptibility, and cardiovascular and metabolic diseases. Here, CYP51A1 is linked to Global developmental delay.